Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Rob Chess
AddedMar 31, 2024
UpdatedMay 31, 2026
Rob Chess

Rob Chess

Board Member, Caltech

CrunchbaseLinkedIn

Rob Chess's Career

Caltech
Caltech

Pasadena, CA, US

Board Member· Board
Nektar Therapeutics
Nektar Therapeutics

San Francisco, CA, US

Board Member· Board
Twist Bioscience
Twist Bioscience

San Francisco, CA, US

Board Member· Board
BigHat Biosciences
BigHat Biosciences

San Mateo, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Rob Chess's Career

Caltech
Caltech
Series D$76.5M5.6k1891Pasadena, CA, US
Board Member· Board

Leadership at Caltech

Kent KresaKent KresaBoard Member
Richard MurrayRichard MurrayBoard Member
Harry AtwaterHarry AtwaterBoard Member
Phil NechesPhil NechesBoard Member
Juan GinerJuan GinerCo-Founder
Evangelos SimoudisEvangelos SimoudisBoard Member

Similar to Caltech

Stanford UniversityStanford UniversityStanford, CA, USEducation, Researchest. 1891Stanford UniversityStanford, CA, US · est. 1891

Stanford University: A prestigious private research institution in California, educating over 17,000 students.

Series B · $20.9M16.7k
University of Southern CaliforniaUniversity of Southern CaliforniaLos Angeles, CA, USEducation, Researchest. 1920University of Southern CaliforniaLos Angeles, CA, US · est. 1920

USC: A prestigious private research university in Los Angeles, serving diverse students globally.

Angel · $2.8M28.9k
UC San DiegoUC San DiegoLos Angeles, CA, USResearchest. 1960UC San DiegoLos Angeles, CA, US · est. 1960

UC San Diego: A leading public research university in La Jolla, California, offering 200+ degree programs.

Pre-Seed · $24.6M16.3k
The University of ChicagoThe University of ChicagoChicago, IL, USEducation, Researchest. 1890The University of ChicagoChicago, IL, US · est. 1890

UChicago: A premier private research university located in Chicago's Hyde Park.

Series A · $197.8M27.5k
Nektar Therapeutics
Nektar Therapeutics
Public$1.2B2161990San Francisco, CA, US
Board Member· Board

Leadership at Nektar Therapeutics

R. Scott GreerR. Scott GreerBoard Member
Howard RobinHoward RobinBoard Member
John S. PattonJohn S. PattonFounder
Roy WhitfieldRoy WhitfieldBoard Member

Similar to Nektar Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Neurona TherapeuticsNeurona TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2008Neurona TherapeuticsSouth San Francisco, CA, US · est. 2008

Neurona Therapeutics: Leading provider of cell-based medicines for neurological disorders.

Series A · $200.3M58
Nerx BiosciencesNerx BiosciencesIndianapolis, IN, USCancer Therapeuticsest. 2009Nerx BiosciencesIndianapolis, IN, US · est. 2009

US-based NĒRx BioSciences Inc, founded in 2009, specializes in discovering and developing targeted cancer therapeutics.

Seed · $500k11
Twist Bioscience
Twist Bioscience
Public$553.1M9892013San Francisco, CA, US
Board Member· Board

Leadership at Twist Bioscience

Bill BanyaiBill BanyaiBoard Member
Bob RagusaBob RagusaBoard Member
Emily LeproustEmily LeproustBoard Member
Xiaoying MaiXiaoying MaiBoard Member
Keith CrandellKeith CrandellBoard Member
Melissa StarovasnikMelissa StarovasnikBoard Member

Similar to Twist Bioscience

Switchback SystemsSwitchback SystemsSan Francisco, CA, USDNA Synthesisest. 2019Switchback SystemsSan Francisco, CA, US · est. 2019

Switchback Systems, a San Francisco-based software startup, specializes in efficient, scalable DNA synthesis platforms.

Seed · $7.1M14
Ansa BiotechnologiesAnsa BiotechnologiesEmeryville, CA, USDNA Synthesisest. 2018Ansa BiotechnologiesEmeryville, CA, US · est. 2018

Ansa Biotechnologies: Pioneering enzyme-based, efficient DNA synthesis.

Series A · $83.4M82
SynthegoSynthegoRedwood City, CA, USCrispr Kits, Gene Editingest. 2012SynthegoRedwood City, CA, US · est. 2012

US-based Synthego Corp. provides software solutions for biological research, primarily serving California.

Series E · $460.5M322
Ginkgo BioworksGinkgo BioworksBoston, MA, USOrganism Designest. 2009Ginkgo BioworksBoston, MA, US · est. 2009

Ginkgo Bioworks: Engineering biology, designing custom organisms for diverse markets.

Public · $1.6B1.3k
BigHat Biosciences
BigHat Biosciences
Series B$99.3M922019San Mateo, CA, US
Board Member· Board

Leadership at BigHat Biosciences

Francisco GimenezFrancisco GimenezBoard Member
Vineeta AgarwalaVineeta AgarwalaBoard Member
Theresa TribbleTheresa TribbleCo-Founder
Denis DovganichDenis DovganichCo-Founder
Peyton GreensidePeyton GreensideCo-Founder
Mark DePristoMark DePristoCo-Founder

Similar to BigHat Biosciences

Abterra BiosciencesAbterra BiosciencesSan Diego, CA, USAntibody Therapeuticsest. 2009Abterra BiosciencesSan Diego, CA, US · est. 2009

Abterra Bio: Pioneering next-gen antibody therapeutics with advanced technology and machine learning.

Seed · $4.4M9
Nabla BioNabla BioBoston, MA, USAntibody Designest. 2020Nabla BioBoston, MA, US · est. 2020

AI-driven design of therapeutic antibodies for complex diseases.

Seed · $11.4M9
AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
TenSixty BiosciencesTenSixty BiosciencesCambridge, MA, USTherapeuticsest. 2021TenSixty BiosciencesCambridge, MA, US · est. 2021

TenSixty BioSciences innovates small molecule therapeutics through high throughput experiments.

Series A · $7.2M50

Rob Chess's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Rob Chess

Mike LynchMike LynchCo-Founder · DMC BiotechnologiesJim NewellJim NewellBoard Member · OsebergRobert BenkowskiRobert BenkowskiFounder · Opsin BiotherapeuticsHansjörg WyssHansjörg WyssCEO · OpsonixBen YerxaBen YerxaCEO · Foundation Fighting BlindnessPaul CastellaPaul CastellaBoard Member · Hera Biotech